Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers seeking to protect patents covering their products. A key factor in each challenge was how to demonstrate commercial success of the product and the nexus between that success and the patents-in-suit with respect to the issue of non-obviousness of the patents-in-suit.
Dr. Bell was supported in these cases by CRA consultants including Andrew Tepperman, Justin Ho, Cavay Ip, Archan Ruparel, and Natalie Nah.
China refines how to determine patent damages
China’s patent law was promulgated in 1984 and amended three times prior to 2020 (in 1992, 2000, and 2008). On October 17, 2020, the National People’s Congress...